Is Sangani Hospital overvalued or undervalued?

As of 18 November 2025, Sangani Hospital's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued based on its financial metrics, with a PE ratio of 37.31, an EV to EBITDA of 36.62, and a ROE of 6.98%. In comparison to its peers, Max Healthcare is considered very expensive with a PE of 77.03, while Apollo Hospitals, which is rated attractive, has a PE of 63.51 and an EV to EBITDA of 33.40.
Given these ratios and the competitive landscape, Sangani Hospital appears to be fairly valued in relation to its peers. While it has shown strong short-term performance with a 1-week return of 6.77% compared to the Sensex's 0.84%, its year-to-date return of -3.77% suggests some challenges ahead. Overall, the company's current valuation reflects a balanced outlook amidst a competitive healthcare market.